论文部分内容阅读
美国FDA于2012年12月10日批准扩大Zytiga(abiraterone acetate,醋酸阿比特龙)适用症范围,即可以在开始化疗之前用于治疗不适宜进行去势疗法的男性晚期(已经转移)前列腺癌。FDA最初于2011年4月批准Zytiga用于经化疗药物紫杉醇治疗后病情仍在继续发展的前列腺癌病人。
On December 10, 2012, the U.S. FDA approved the extension of the Zytiga (abiraterone acetate) indications for the treatment of advanced (metastatic) prostate cancer in men who are unfit for ovariectomies prior to initiating chemotherapy. The FDA initially approved Zytiga in April 2011 for prostate cancer patients whose condition continues to develop following chemotherapy with paclitaxel.